[Invasive fungal infections in patients after liver transplantation].
Advances in surgical technique, immunosuppression, and medical management have greatly improved clinical results after liver transplantation (LTx). Fungal infections in LTx-patients still represent serious complications and are associated with a significant decrease in survival. The majority of fungal infections in LTx-patients are caused by Candida species, which is explained by the major abdominal surgery. Aspergillus infections are second common, whereas other fungal infections such as pneumocystosis, cryptococcosis, or zygomycosis represent rare events. The high mortality of invasive fungal infections in LTx-recipients is explained by the severity of the underlying medical condition and by difficulties in diagnosis and medical therapy. Currently available diagnostic tests do not allow a timely and reliable diagnosis of invasive fungal infections in LTx-patients. Amphotericin B has been the standard treatment for invasive candidiasis and aspergillosis for many years but the high frequency of side effects limits its application. Fluconazole is widely used due to better tolerability and fewer drug interactions. Disadvantages are the lack of activity against Aspergillus species and the selection of resistant Candida strains. Progress is to be expected from new antimycotic agents belonging to azoles (voriconazole) and echinocandins (caspofungin) as these are less toxic and have a broad range of antimycotic activity. Analysis of prognostic factors allows identifying LTx-patients at high risk for invasive fungal infection. Antimycotic prophylaxis or pre-emptive therapy may improve clinical outcome in this patient subgroup.
Fischer
L
L
Klinik für hepatobiliäre Chirurgie und viszerale Transplantation, Universitätsklinikum Hamburg Eppendorf, D-20246 Hamburg, Germany. lfischer@uke.uni-hamburg.de
Sterneck
M
M
D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D001230:Aspergillus; D002175:Candida / Q000145:classification; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D018890:Chemoprevention; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D012307:Risk Factors
D000935:Antifungal Agents